Skip to content

FDA temperature-management recalls: design lessons for AIRCHILL risk management

What changed

In August 2026 the US FDA published Class II recalls affecting temperature-management systems including Blanketrol II Model 222S and Innercool CoolBlue Model STx. The reported issue involved possible overheating of a CPU board followed by loss of device function during temperature therapy.

Why this matters for AIRCHILL

This is not evidence against temperature management. It is directly relevant to device risk management and architecture. A future AIRCHILL system should explicitly address loss of cooling performance, thermal or electronic component overheating, alarm behaviour, safe shutdown and continued ventilation if the cooling subsystem fails.

Engineering and regulatory implication

These scenarios should be reflected in ISO 14971 risk management, FMEA/FMECA and verification planning, including:

  • cooling-function loss,
  • controller/CPU overheating,
  • sensor or control-loop failure,
  • alarm latency and alarm visibility,
  • safe fallback temperature behaviour,
  • separation of ventilation-critical and cooling-critical functions where appropriate,
  • recovery and alternative-treatment procedures.

Source: US Food and Drug Administration, August 2026 recall notices. https://www.fda.gov/

AIRCHILL is a development-stage technology with no FDA clearance or CE mark.